Cerev­el failed to draw Pfiz­er in­to a bid­ding war, but got Ab­b­Vie to up its price any­way, fil­ing shows

Ab­b­Vie’s $45-per-share, $8.7 bil­lion ac­qui­si­tion of the neu­ro­science drug de­vel­op­er Cerev­el Ther­a­peu­tics was $10 per share high­er than its ini­tial bid, ac­cord­ing to de­tails in an SEC fil­ing, as the big phar­ma upped its price de­spite a lack of for­mal of­fers from oth­er suit­ors.

The fil­ing de­tails sev­er­al months of ne­go­ti­a­tions be­tween Cerev­el and oth­er com­pa­nies when it first ex­plored a re­gion­al part­ner­ship in Japan for its lead schiz­o­phre­nia and Alzheimer’s dis­ease psy­chosis drug. Those talks even­tu­al­ly fell apart but would be re­born as full-fledged takeover dis­cus­sions that led to the deal an­nounced late last year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER